FDA Accepts Dyne BLA for z-Rostudirsen in DMD
The FDA accepts Dyne BLA z-rostudirsen for people with Duchenne muscular dystrophy amenable to exon 51 skipping. Dyne's July 20, 2026 release said the agency granted Priority Review, set a January 21, 2027 PDUFA date, and is reviewing an Accelerated Approval package built on dystrophin from the DELIVER trial.
Contents10 sections
Key Takeaways
- FDA accepted Dyne's BLA for z-rostudirsen (DYNE-251) in exon 51–amenable DMD and granted Priority Review with a January 21, 2027 PDUFA date.
- The filing seeks Accelerated Approval using dystrophin as a surrogate endpoint from DELIVER's registrational expansion cohort.
- Dyne said once-every-4-weeks dosing produced a statistically significant dystrophin increase with functional improvement signals and a favorable safety profile in that cohort.
- Confirmatory work continues in DELIVER's long-term extension and Phase 3 FORZETTO (NCT07608432).
z-Rostudirsen (DYNE-251) at a glance
| Field | Detail |
|---|---|
| Drug | Zeleciment rostudirsen (z-rostudirsen, DYNE-251) |
| Company | Dyne Therapeutics, Inc. |
| FDA action | BLA accepted; Priority Review; PDUFA January 21, 2027 |
| Population | DMD with mutations amenable to exon 51 skipping |
| Modality | TfR1-targeted Fab–PMO conjugate for exon 51 skipping |
| Key trial | DELIVER Phase 1/2 (NCT05524883) |
| Confirmatory | FORZETTO Phase 3 (NCT07608432) |
What did the FDA accept?
Dyne said the FDA accepted for review a Biologics License Application for z-rostudirsen in individuals with DMD amenable to exon 51 skipping. Priority Review shortens the review clock; the assigned PDUFA target action date is January 21, 2027.
The company's disclosure is in Dyne's July 20 GlobeNewswire BLA acceptance release.
What is the Accelerated Approval basis?
Dyne said the BLA seeks Accelerated Approval based on dystrophin as a surrogate endpoint. The registrational expansion cohort of global Phase 1/2 DELIVER met its primary endpoint. The company reported robust, statistically significant dystrophin production with once-every-4-weeks dosing, functional improvement across multiple clinical endpoints, and a favorable safety profile in that cohort.
DELIVER is registered as ClinicalTrials.gov NCT05524883 (DYNE-251 / DELIVER).
How is z-rostudirsen designed?
Z-rostudirsen conjugates a phosphorodiamidate morpholino oligomer to a Fab that binds transferrin receptor 1. Dyne said the design aims to deliver near-full-length dystrophin production in muscle and the central nervous system.
- Prior FDA designations cited: Breakthrough Therapy, Fast Track, Rare Pediatric Disease, and Orphan Drug
- Orphan Drug also cited from EMA and Japan's MHLW
- Pipeline exons in development: 53, 45, 44, and 55 (DYNE-253/245/244/255)
What comes next commercially and clinically?
Dyne said it expects a potential U.S. launch in Q1 2027 if approval lands on the PDUFA timeline and that launch preparations continue. The product remains investigational until approved. Confirmatory evaluation continues in DELIVER's long-term extension and in Phase 3 FORZETTO (NCT07608432).
Dyne estimated about 12,000 people with DMD in the U.S. and 16,000 in the EU, with symptoms typically emerging between ages 3 and 5.
What remains uncertain?
Accelerated Approval, if granted, would still require confirmatory clinical benefit. The company release does not publish full numerical dystrophin percentages or primary functional endpoint deltas in the acceptance announcement; those details live in prior data disclosures and the BLA. Manufacturing, labeling, and REMS-style postmarketing commitments—if any—will only be known at approval.
Related NovaPharma coverage
- FDA CBER Patient Listening Meeting on Gene Therapy Safety
- FDA approves Merck oral PCSK9 drug
- FDA Activity Round Up July 2026
Frequently Asked Questions
What did the FDA accept for Dyne's z-rostudirsen?
On July 20, 2026, Dyne said the FDA accepted its Biologics License Application for zeleciment rostudirsen (z-rostudirsen, DYNE-251) for Duchenne muscular dystrophy amenable to exon 51 skipping, granted Priority Review, and set a PDUFA date of January 21, 2027.
What evidence supports the z-rostudirsen BLA?
Dyne said the BLA seeks Accelerated Approval based on dystrophin as a surrogate endpoint from the registrational expansion cohort of the Phase 1/2 DELIVER trial (NCT05524883), which met its primary endpoint with once-every-4-weeks dosing.
When could z-rostudirsen launch if approved?
Dyne said it continues to expect a potential U.S. launch in Q1 2027 if approval arrives on the January 21, 2027 PDUFA timeline, while confirmatory work continues in the DELIVER long-term extension and the Phase 3 FORZETTO trial (NCT07608432).
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for z-rostudirsen.
Unlock full calendar →Dyne Therapeutics pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
Deeper reading
Industry reports & whitepapers
- FDA CBER Patient Listening Meeting on Gene Therapy Safety: Patient and Care Partner Perspectives — Patient and care partner perspectives inform FDA’s thinking on approved gene therapy safety and long…